CD274 and non-small cell lung carcinoma: In a retrospective analysis of 54 patients with NSCLC who received nivolumab or pembrolizumab, no patients with 6-week post-treatment NLR ≥5 achieved PR (regardless of PD-L1 expression), whereas 42% of patients with post-treatment NLR <5 achieved PR (p = 0.011), suggesting that NLR ≥5 may identify non-responders at 6 weeks post-nivolumab and -pembrolizumab therapy.